Article
A multicenter study to clarify the optimal HCV-RNA negative period during combined therapy with pegylated interferon plus ribavirin in patients with chronic hepatitis caused by HCV genotype 2.
Internal medicine (Tokyo, Japan) - 1 Jan 2012
Nagoshi Sumiko, Koshima Yohei, Nakamura Ikuo, Funyu Junji, Sekine Chuichi, Harada Youji, Nishikawa Ko, Yoshida Takeshi, Matsui Atsushi, Sotome Naoki, Toshima Kenichi, Takegoshi So, Shiomi Masao, Tanaka Masahiko, Saito Akira, Fujiwara Kenji, Mochida Satoshi
Abstract excerpt
OBJECTIVE: A multicenter open trial was performed to clarify the optimal duration of combined pegylated interferon (Peg-IFN) plus ribavirin therapy in patients with chronic hepatitis caused by HCV genotype 2. METHODS: A total of 100 patients seen between 2005 and 2007 received the combination therapy for 4 to 52 weeks. The cutoff value of the HCV-RNA-negative (titers under 1.7 Log IU/mL) period during the therapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.